Startseite

Sirolimus

Sirolimus

Spezifikationen

53123-88-9CAS-Nummer
610-965-5EG-Nummer
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraIUPAC-Name
C51H79NO13Chemische Formel
914.2 g/molMolekulargewicht
rapamycin; Sirolimus; Rapamune; (-)-Rapamycin; 53123-88-9; rapalimus; AY-22989; WY-090217; FYARRO; HYFTOR; sirolimusum; Npc-12g; Antibiotic AY 22989; RAPA; Rapammune; SILA 9268A; W36ZG6FT64; L04AA10; NSC-226080; CHEBI:9168; SM-88 COMPONENT SIROLIMUS; AY 22989; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; DTXSID5023582; NSC226080; NSC 226080; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; DTXCID503582; Wy 090217; (2S)-2-(((2R)-2-((2R,3R,4R,5S,6R)-3-acetamido-2-((((2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl)methoxy-hydroxy-phosphoryl)oxy-hydroxy-phosphoryl)oxy-5-hydroxy-6-(hydroxymethyl)tetrahydropyran-4-yl)oxypropanoyl)amino)propanoic acid; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-((2R)-1-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)propan-2-yl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido(2,1-c)(1,4)oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; RefChem:6226; S01XA23; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((2R)-1-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)propan-2-yl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone; I2190A; I 2190A; AY 22 989; (1R,15R,16E,18R,19R,21R,23S,24Z,26E,28E,30S,35R)-1,18-dihydroxy-12-((2R)-1-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)propan-2-yl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone; 1,18-dihydroxy-12-(1-(4-hydroxy-3-methoxycyclohexyl)propan-2-yl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone; 9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,2; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone, 9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-(3-(4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-, (3S-(3R*(S*(1R*,3S*,4S*)),6S*,7E,9S*,10S*,12S*,14R*,15E,17E,19E,21R*,23R*,26S*,27S*,34aR*))-; I-2190A; SIIA 9268A; Rapamycin (Sirolimus); Rapamycin (GMP); Rapamycin (GMP Like); MFCD00867594; DE-109; C51H79NO13; Rapamycin (>85%); M02444; Supralimus; Rapamycin/Sirolimus; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-{(2S)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone; Perceiva; Cypher; CCRIS 9024; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine solution; HSDB 7284; 1fkb; 1pbk; NCGC00021305-05; LCP-Siro; (9S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-{(2R)-1-[(3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone; RAP; Rapamycin (Standard); S1039; Rapamycin (Sirolimus)?; SIROLIMUS [INN]; SIROLIMUS [JAN]; RAPAMYCIN [MI]; Human Blood - Sirolimus; SIROLIMUS [HSDB]; SIROLIMUS [USAN]; SIROLIMUS [VANDF]; BiomolKI2_000084; SIROLIMUS [MART.]; SIROLIMUS [USP-RS]; SIROLIMUS [WHO-DD]; Rapamycin,Sirolimus,Rapamune; UNII-W36ZG6FT64; BIDD:PXR0165; SIROLIMUS [EMA EPAR]; MLS006010168; Sirolimus [USAN:INN:BAN]; Rapamycin - Bio-X trade mark; GTPL6031; orb1308282; orb3141207; SIROLIMUS [ORANGE BOOK]; BDBM36609; MS-R001; GLXC-06448; HMS2089A21; HMS3403F11; HMS3884C03; HY-10219GL; RAPAMYCIN (AY-22989); EX-A1044; RPM; traene-2,3,10,14,20-pentone; AC-722; BDBM50064359; HB2779; HY-10219G; HY-10219R; LMPK06000003; STL570275; SIROLIMUS COMPONENT OF SM-88; AKOS015850976; AKOS015961618; AE27685; CCG-100684; CS-0063; DB00877; NAB-RAPAMYCIN COMPONENT RAPAMYCIN; NSC-2260804; NCGC00021305-06; NCGC00021305-07; AS-11687; BR164324; HY-10219; SMR004701276; Fyarro (sirolimus albumin-bound particles); EVEROLIMUS IMPURITY A [EP IMPURITY]; UNM-0000358684; A-275; AY-22989,SIROLIMUS,WY-090217; CS-0626126; CS-1010374; R0097; NSC-2260804,AY-22989; Rapamycin, VETRANAL(TM), analytical standard; EC 610-965-5; Q32089; 23R*,26S*,27S*,34AR*]]-RAPAMYCIN; BRD-K84937637-001-04-0; BRD-K84937637-001-06-5; BRD-K84937637-001-09-9; BRD-K84937637-001-11-5; BRD-K84937637-001-13-1; BRD-K89626439-001-01-0; SIROLIMUS COMPONENT OF NAB-RAPAMYCIN RAPAMYCIN; Z2568665260; azatricyclo[30.3.1.0^{4,9}]hexatriaconta-16,24,26,28-te; 24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypy; Rapamycin from Streptomyces hygroscopicus, >=95% (HPLC), powder; Rapamycin from Streptomyces hygroscopicus, Vetec(TM) reagent grade, >=95%; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxy-cyclohexyl]-1-methyl-ethyl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-{(2S)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34 aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hex adecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydro xy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy- 6,8,12,14,20,26-hexamethyl-23,27-ep; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-4,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-223,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(6H,31H)-pentone; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,; [3S-[3R*[S* (1R*,3S*,4S*)],6S*,7E,9S*,10S*,12S*,14R*,15E,17E,19E,21R*; 1,18-Dihydroxy-12-[2-(4-hydroxy-3-methoxy-cyclohexyl)-1-methyl-ethyl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-aza-tricyclo[30.3.1.0*4,9*]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone (Rapamycin); 25,26,27,32,33,34,34A-HEXADECAHYDRO-9,27-DIHYDROXY- 3-[2-(4-HYDROXY-3-METHOXYCYCLOHEXYL)-1-METHYLETHYL]- 10,21-DIMETHOXY-6,8,12,14,20,26-HEXAMETHYL-; SIROLIMUSRAPAMUNERAPAMYCIN(-)-RAPAMYCINANTIBIOTIC AY 22989SIIA 9268AAY 22989WY 09021723,27-EPOXY-3H-PYRIDO[2,1-C][1,4]OXAAZACYCLOHENTRIACONTINE- 1,5,11,28,29(4H,6H,31H)-PENTONESynonyme